Need Assistance?

  • US & Canada:
    +
  • UK: +
Cyclization Modification

Introduction

Peptides play an important role in regulating the functional activities of various systems, organs, tissues and cells in the body and in life activities, and are often used in disease research, cosmetics, drug research and development and other fields. Peptides can be divided into cyclic and linear peptides according to whether they are cyclic or not. The synthesis technology of linear peptides is very mature. The synthesis of linear peptides consisting of hundreds of amino acids has been achieved. Although many linear peptides have good biological activity and stability in vitro, the linear peptides are degraded under the action of enzymes after entering the body, which eventually leads to the loss of their activity.

With the deepening of the understanding of life phenomena and protein functions, and the expansion of the demand for lead compounds and various functional materials for drug design, people pay more attention to peptides with special structures and special properties. Among a wide variety of peptide compounds, cyclic peptides are an extremely important one. Cyclic peptides have a well-defined fixed conformation, are more rigid than linear peptides, and exhibit stronger affinity for target receptors. In addition, the absence of free amino and carboxyl groups in the cyclic peptide molecule greatly reduces its sensitivity to enzymes. The special structure of cyclic peptides and the stability to enzymatic degradation make them widely used in biomedicine, medicine, nanomaterials, supramolecular self-assembly and other fields.

Cyclization is the most direct way to synthesize cyclic peptides, especially for peptides with larger structural backbones. Generally, the cyclization of peptides containing 7 or more amino acids is relatively smooth, and the cyclization of peptides containing less than 7 amino acids is difficult.

Commonly Used Cyclization Methods

According to the cyclization method of cyclic peptides, it can be divided into side chain -to-side chain type, head-to-tail type, side chain-to-end type, and disulfide-bridge, etc.

(1) Side chain-to-side chain

This cyclization method involves the formation of amide structures between aspartic acid or glutamic acid residues and the base amino acid. Side chain protecting groups must be selectively removable, whether the peptide is on resin or after dissociation. In addition, this cyclization method can also form diphenyl ethers via tyrosine or p-hydroxyphenylglycine.

Side chain-to-side chain Side chain-to-side chain

(2) Disulfide-bridge

This cyclization was introduced by deprotection of a pair of cysteine residues followed by oxidation to form a disulfide bond. The synthesis of multiple rings can be achieved by selectively removing the thiol protecting group. Cyclization can be done either in the solvent after dissociation or on the resin before dissociation.

Cyclization Modification

(3) Side chain-to-end

This cyclization method typically involves the C-terminus of a linear peptide with the amino group of a lysine or ornithine side chain, or the N-terminus of a linear peptide with a carboxyl group of an aspartic acid or glutamic acid side chain. In addition, this cyclization method also involves the formation of ether bonds between the C-terminus of linear peptides and the side chains of serine or threonine.

Side chain-to-end Side chain-to-end

(4) Head-to-tail

End-to-end cyclic peptides are usually condensed into a ring by the N-terminal amino group and C-terminal carboxyl group of the linear peptide. The type and number of amino acids in linear peptides play a crucial role in the ease of cyclization and the yield of cyclic peptides. Linear peptides can be cyclized in a solvent or immobilized on a resin by side chain cyclization.

Head-to-tail Head-to-tail

FDA Approved Cyclic Peptide Drugs

In the future, some applications of cyclic peptides in the pharmaceutical industry are expected to surpass small molecules and antibodies.

The following are cyclic peptides approved for clinical use between 2001 and 2021:

  • Cyclic peptide drugs targeting intracellular proteins
NameCASCatalog No.Price
Romidepsin128517-07-7BAT-010096Inquiry
  • Cyclic peptide drugs targeting extramembrane proteins
NameCASSequencePrice
Linaclotide851199-59-2C(1)C(2)EYC(3)C(1)NPAC(2)TGC(3)YInquiry
Plecanatide467426-54-6NDEC(1)ELC(2)VNVAC(1)TGC(2)LInquiry
Pasireotide396091-73-9cyclo[Hyp(Unk)-Phg-D-Trp-Lys-Tyr(Bn)-Phe]Inquiry
Lanreotide108736-35-2XC(1)YWKVC(1)XInquiry
Terlipressin14636-12-5GGGC(1)YFQNC(1)PKGInquiry
Bremelanotide189691-06-3Nle-D(1)HFRWK(1)Inquiry
Setmelanotide920014-72-8RC(1)AHFRWC(1)Inquiry
  • Antimicrobial Cyclic Peptides
NameCASSequencePrice
Daptomycin103060-53-3WNDTGKDADGSEYInquiry
Dalbavancin171500-79-1Inquiry
Caspofungin162808-62-0Inquiry

Other Cyclic Peptide Products

Cyclic peptides are attracting more and more attention as a unique molecular class.

The following are other related cyclic peptide molecules:

NameCASSequencePrice
KRpep-2dInquiry
H-Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu-Cys-OH (Disulfide bond)244082-19-7CTTHWGFTLC (Disulfide Bridge: Cys1-Cys10)Inquiry
Siamycin I164802-68-0cyclo{CLGVGSCND}FAGCGYAIVCFW (Disulfide bridge: Cys1-Cys13, Cys7-Cys19)Inquiry
Compstatin206645-99-0IC(1)VVQDWGHHRC(1)TInquiry
Fmoc-HPra-OH942518-21-0Inquiry
BMSpep-571629655-80-6{mercaptoacetic acid}-FANPHLSWSW-{norleucine}-{norleucine}-RCG (Sulfide bridge:mercaptoacetic acid 1-Cys15)Inquiry
Cyclic citrullinated peptideInquiry
Bacteriocin As-48AKEFGIPAAVAGTVLNVVEAGGWVTTIVSIInquiry
Tricyclic peptide MS-271NH2(1)-C(2)LGVGSC(3)ND(1)FAGC(2)GYAIVC(3)FWInquiry
Vhl-1(cyclo)-SISC(1)GESC(2)AMISFC(3)FTEVIGC(1)SC(2)KNKVC(3)YLN-(cyclo)Inquiry
Vhl-2(cyclo)-GLPVC(1)GETC(2)FTGTC(3)YTNGC(1)TC(2)DPWPVC(3)TRN-(cyclo)Inquiry
Vhr1(cyclo)-GIPC(1)AESC(2)VWIPC(3)TVTALLGC(1)SC(2)SNKVC(3)YN-(cyclo)Inquiry
Viba 15(cyclo)-GLPVC(1)GETC(2)VGGTC(3)NTPGC(1)AC(2)SWPVC(3)TRN-(cyclo)Inquiry
Viba17(cyclo)-GLPVC(1)GETC(2)VGGTC(3)NTPGC(1)GC(2)SWPVC(3)TRN-(cyclo)Inquiry
Vico A(cyclo)-GSIPC(1)AESC(2)VYIPC(3)FTGIAGC(1)SC(2)KNKVC(3)YYN-(cyclo)Inquiry
Vico B(cyclo)-GSIPC(1)AESC(2)VYIPC(3)ITGIAGC(1)SC(2)KNKVC(3)YYN-(cyclo)Inquiry
Viphi A(cyclo)-GSIPC(1)GESC(2)VFIPC(3)ISSVIGC(1)AC(2)KSKVC(3)YKN-(cyclo)Inquiry
Viphi D(cyclo)-GIPC(1)GESC(2)VFIPC(3)ISSVIGC(1)SC(2)SSKVC(3)YRN-(cyclo)Inquiry
Viphi E(cyclo)-GSIPC(1)GESC(2)VFIPC(3)ISAVIGC(1)SC(2)SNKVC(3)YKN-(cyclo)Inquiry
Viphi F(cyclo)-GSIPC(1)GESC(2)VFIPC(3)ISAIIGC(1)SC(2)SSKVC(3)YKN-(cyclo)Inquiry
Viphi G(cyclo)-GSIPC(1)GESC(2)VFIPC(3)ISAIIGC(1)SC(2)SNKVC(3)YKN-(cyclo)Inquiry
Murepavadin TFACyclo(AS-d-Pro-PTWI-Dab-Orn-d-Dab-Dab-W-Dab-Dab).TFAInquiry
PDZ1 Domain inhibitor peptide1315378-73-4YKK(1)TEA(1)V (Modifications: Ala-6 = β-Ala)Inquiry

Online Inquiry

Verification code
Inquiry Basket